BioCentury | Dec 22, 2020
Targets & Mechanisms

Tissue-targeting autoantibodies as a driver of long COVID

...immune cell surface markers; proteins expressed on vascular...
BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

...the immunoglobulin-like cell surface receptor RAGE, contributes to vascular...
BioCentury | Dec 10, 2020
Product Development

Vaccines aren’t enough: COVID R&D’s adaptive platform trial aims to fill the need for new therapies

...continue adding new therapies including antivirals and vascular...
...peptides. Bradykinins have been shown to cause vascular...
BioCentury | Dec 5, 2020
Product Development

Dec. 4 Quick Takes: Zogenix in Dravet deal with start-up; plus updates from BioCryst, Takeda, AB Science, Sutro, Lilly, Cedars-Sinai

...with the facility to manufacture banks of stem cells that could be used to repair vascular...
BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

...The company also said Charles Semba has joined as CMO. Semba is an adjunct professor of vascular...
BioCentury | Nov 14, 2020
Regulation

BioMarin withdraws MAA for hemophilia gene therapy following safety, durability concerns

...1 IFNγ – Interferon γIL-3 – Interleukin-3VEGF – Vascular...
BioCentury | Nov 14, 2020
Deals

Innovation in a hurry: China biotechs see a fast track to global stage – survey

...CD279) – Programmed cell death 1VEGF – Vascular...
BioCentury | Nov 11, 2020
Emerging Company Profile

CatalYm: opening up tumors to immune cells

...inhibits LFA-1 activation on immune cells. This prevents LFA-1 from interacting with ICAM-1 on the vascular...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...Tumor-associated calcium signal transducer 2VEGF - Vascular...
BioCentury | Oct 30, 2020
Distillery Therapeutics

Targeting water channel AQP1 for hypertrophic cardiomyopathy

...Quang, Staff Writer DISEASE CATEGORY: CardiovascularINDICATION: CardiomyopathyInhibiting AQP1, a water channel expressed in cardiac and vascular...
Items per page:
1 - 10 of 4500
BioCentury | Dec 22, 2020
Targets & Mechanisms

Tissue-targeting autoantibodies as a driver of long COVID

...immune cell surface markers; proteins expressed on vascular...
BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

...the immunoglobulin-like cell surface receptor RAGE, contributes to vascular...
BioCentury | Dec 10, 2020
Product Development

Vaccines aren’t enough: COVID R&D’s adaptive platform trial aims to fill the need for new therapies

...continue adding new therapies including antivirals and vascular...
...peptides. Bradykinins have been shown to cause vascular...
BioCentury | Dec 5, 2020
Product Development

Dec. 4 Quick Takes: Zogenix in Dravet deal with start-up; plus updates from BioCryst, Takeda, AB Science, Sutro, Lilly, Cedars-Sinai

...with the facility to manufacture banks of stem cells that could be used to repair vascular...
BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

...The company also said Charles Semba has joined as CMO. Semba is an adjunct professor of vascular...
BioCentury | Nov 14, 2020
Regulation

BioMarin withdraws MAA for hemophilia gene therapy following safety, durability concerns

...1 IFNγ – Interferon γIL-3 – Interleukin-3VEGF – Vascular...
BioCentury | Nov 14, 2020
Deals

Innovation in a hurry: China biotechs see a fast track to global stage – survey

...CD279) – Programmed cell death 1VEGF – Vascular...
BioCentury | Nov 11, 2020
Emerging Company Profile

CatalYm: opening up tumors to immune cells

...inhibits LFA-1 activation on immune cells. This prevents LFA-1 from interacting with ICAM-1 on the vascular...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...Tumor-associated calcium signal transducer 2VEGF - Vascular...
BioCentury | Oct 30, 2020
Distillery Therapeutics

Targeting water channel AQP1 for hypertrophic cardiomyopathy

...Quang, Staff Writer DISEASE CATEGORY: CardiovascularINDICATION: CardiomyopathyInhibiting AQP1, a water channel expressed in cardiac and vascular...
Items per page:
1 - 10 of 4500